Physician

Darla Kaye Liles, MD

According to 2025 Medicare claims, Darla Liles, MD (NPI: 1528051729) practices hematology, with the plurality of this provider's patient population coming from Lenoir, NC. This provider's primary affiliated billing organization is VIDANT MEDICAL GROUP LLC (NPI: 1477648731; TIN: 383740839) and primary practice location at 27834-2818. Liles is affiliated with the Coastal Plains Network, LLC (ACO ID: A2684), participating under the MSSP model.

Liles' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 333 traditional Medicare patients, billed 960 HCPCS/CPT codes, and received $63,202 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 2,469 prescription claims across 235 beneficiaries totaling $8,341,525 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 42 claims. Open Payments data shows 201 records totaling $800,662. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $117,985 and ending at $63,202. Concurrently, Part D prescription costs have risen steadily, from $2,629,473 to $8,341,525. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $3,322 to $2,284.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	510	5,046	$117,985
2016	406	4,654	$102,733
2017	378	4,306	$83,545
2018	322	1,397	$50,737
2019	294	734	$41,622
2020	305	737	$42,322
2021	253	658	$44,816
2022	342	2,321	$109,566
2023	289	732	$45,157
2024	333	960	$63,202

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	170	1,150	$2,629,473
2016	147	1,284	$3,086,971
2017	139	1,148	$3,365,577
2018	128	1,024	$4,041,588
2019	106	911	$4,120,364
2020	163	1,898	$4,754,593
2021	160	1,909	$4,633,487
2022	222	1,965	$6,122,331
2023	238	2,117	$5,803,590
2024	235	2,469	$8,341,525

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$1,019
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	54	$7,299
2021	N/R	42	$2,559
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	71	83	$103
M0010	Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services	90	343	$71
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	93	187	$70
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	35	99	$61
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	57	66	$44

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	149	4,137	$2,806,258
Imbruvica	Ibrutinib	40	1,141	$607,325
Pomalyst	Pomalidomide	28	784	$595,495
Oxbryta	Voxelotor	60	1,800	$563,162
Calquence	Acalabrutinib Maleate	40	1,200	$524,528

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$28	Masimo Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	199	$800,634	Takeda Pharmaceuticals U.S.A., Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

Hematology providers
Providers within practice ZIP code 27834-2818
Providers whose plurality patient county is Lenoir, NC
Providers in North Carolina whose primary affiliated billing organization is VIDANT MEDICAL GROUP LLC
Providers in North Carolina affiliated with Coastal Plains Network, LLC (MSSP)

FAQ

What Medicare data is available for Darla Kaye Liles, MD?

Tedicare shows public-source Medicare data for Darla Kaye Liles, MD (NPI 1528051729), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Darla Kaye Liles, MD have ACO affiliation data?

Darla Kaye Liles, MD is shown with ACO affiliation data for Coastal Plains Network, LLC (MSSP, ACO ID A2684).

What billing organization is linked to Darla Kaye Liles, MD?

Darla Kaye Liles, MD is linked to VIDANT MEDICAL GROUP LLC (billing NPI 1477648731) in the available physician profile data.

Does Darla Kaye Liles, MD have Open Payments data?

Darla Kaye Liles, MD has 201 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.